# US 2013/0251673 A1 · Hepatitis b antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251673 A1
- Document ID: US20130251673A1
- Status: Published application
- Kind: A1
- Application number: 13/723,869
- Filed: 2012-12-21
- Published: 2013-09-26
- Earliest claimed: 2011-12-21
- Assignees: Novira Therapeutics, Inc.
- Inventors: George D. HARTMAN; Osvaldo A. FLORES
- Web page: https://patentgrep.com/patent/US20130251673A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 38/21: Interferons {[IFN]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 211/46: Aniline
- C07C 211/48: N-alkylated amines
- C07C 211/50: with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 311/46: Y being a hydrogen or a carbon atom
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 207/48: Sulfur atoms
- C07D 211/22: by oxygen atoms
- C07D 211/32: by oxygen atoms
- C07D 211/42: attached in position 3 or 5
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/48: having an acyclic carbon atom attached in position 4
- C07D 211/50: Aroyl radical
- C07D 211/52: having an aryl radical as the second substituent in position 4
- C07D 211/58: attached in position 4
- C07D 211/62: attached in position 4
- C07D 211/96: Sulfur atom
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/82: in position 3
- C07D 265/30: not condensed with other rings
- C07D 265/32: with oxygen atoms directly attached to ring carbon atoms
- C07D 295/195: Radicals derived from nitrogen analogues of carboxylic acids
- C07D 295/26: Sulfur atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

## Claims

### Claim 1

A compound of Formula IV:
or pharmaceutically acceptable salts thereof;
wherein
R4 is H or C1-C6 alkyl;
wherein each R5 is independently selected at each occurrence from the group consisting of CH3, C1-C6 alkoxy, halo, —CN, —NO2, -(L)m-SR9, -(L)m-S(═O)R9, -(L)m-S(═O)2R9, -(L)m-NHS(═O)2R9, -(L)mC(═O)R9, -(L)m-OC(═O)R9, -(L)mCO2R8, -(L)m-OCO2R8, -(L)m-N(R8)2, -(L)m-C(═O)N(R8)2, -(L)m-OC(═O)N(R8)2, -(L)m-NHC(═O)NH(R8), -(L)m-NHC(═O)R9, -(L)m-NHC(═O)OR9, -(L)m-C(OH)(R8)2, -(L)mC(NH2)(R8)2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl and —C1-C6 trihaloalkyl;
L is independently, at each occurrence, a bivalent radical selected from —(C1-C3 alkylene)-, —(C3-C7 cycloalkylene)-, —(C1-C3 alkylene)m-O—(C1-C3 alkylene)m-, or —(C1-C3 alkylene)m-NH—(C1-C3 alkylene)m-;
each R8 is independently, at each occurrence, H, C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R2;
R9 is C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 0-5 substituents selected from R2;
R10 is OH, C1-C6 alkyl, C1-C6 alkyl-OH, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R11 is a bond or C1-C3 alkylene, wherein the C1-C3 alkylene is optionally substituted with 1-3 substituents selected from R2;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl;
w is 0, 1 or 2;
each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4;
each occurrence of y is independently selected from the group consisting of 1, 2, and 3;
each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3;
each occurrence of m is independently 0, 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound of Formula IV is of the Formula IVa:
or pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein
each R5 is independently selected at each occurrence from the group consisting of CH3, C1-C6 alkoxy, halo, —CN, —NO2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 and trihaloalkyl;
R10 is OH, halo, C1-C6 alkyl, C1-C6 alkyl-OH, —C1-C6 chloroalkyl, —C1-C6 dichloroalkyl, —C1-C6 trichloroalkyl, —C1-C6 fluoroalkyl, —C1-C6 difluoroalkyl, —C1-C6 trifluoroalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R11 is a bond or C1-C3 alkylene, wherein the C1-C3 alkylene is optionally substituted with 1-3 substituents selected from R2;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, C(O)—C1-C6 alkyl, and C(O)—C1-C6 alkoxy.

### Claim 4 (depends on 1)

The compound of claim 1, wherein each R5 is independently selected at each occurrence from the group consisting of CH3, C1-C6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;
R10 is OH, halo, C1-C6 alkyl, C1-C6 alkyl-OH, C1-C6 fluoroalkyl, C1-C6 difluoroalkyl, C1-C6 trifluoroalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cyclo alkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R11 is a bond or C1-C3 alkylene;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl, and C(O)—C1-C6 alkoxy.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R5 is 3-F, 3-Cl, 3-CH3, 3-CH2F, 3-CHF2, 4-F, 3-CH3-4-F, 3-Cl-4-F, 3-Br-4-F, 3,4,5-trifluoro, 3,4,5-trichloro, or 3-chloro-4,5-difluoro.

### Claim 6 (depends on 1)

The compound of claim 1, wherein w is 1 or 2.

### Claim 7 (depends on 1)

The compound of claim 1, wherein
R11 is a bond or C1-C3 alkylene;
R10 is OH, halo, C1-C6 alkyl, C1-C6 alkyl-OH, —C1-C6 chloroalkyl, —C1-C6 dichloroalkyl, —C1-C6 trichloroalkyl, —C1-C6 fluoroalkyl, —C1-C6 difluoroalkyl, —C1-C6 trifluoroalkyl, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl, or phenyl, wherein the C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, or phenyl groups are optionally substituted with 1-5 substituents selected from halo, —C1-C6 alkyl, and —C1-C6 alkoxy; and
z is 0 or 1.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is of the Formula IVb:
and pharmaceutically acceptable salts thereof;
wherein G1 is independently selected at each occurrence from CH3, OCH3, halo, CF3, CCl3, CH2Cl, CCl2H, CF2H, CH2F, and CF3;
G2 is H, C1-C4 alkyl, or halo;
G3 is OH, CH2OH, or CH2CH2OH;
G4 is H, OH, halo, C1-C6 alkyl, C1-C6 alkyl-OH, —C1-C6 chloroalkyl, —C1-C6 dichloroalkyl, —C1-C6 trichloroalkyl, —C1-C6 fluoroalkyl, —C1-C6 difluoroalkyl, —C1-C6 trifluoroalkyl, or phenyl, wherein the phenyl group is optionally independently substituted with 1-5 substituents selected from halo, —C1-C6 alkyl, and —C1-C6 alkoxy; and
y is 1, 2, or 3.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is of the Formula IVc:
or pharmaceutically acceptable salts thereof;
wherein X is halo;
G1 is hydrogen or halo;
G2 is H, C1-C4 alkyl, or halo; and
G4 is H, halo, C1-C4 alkyl, or OH.

### Claim 10 (depends on 8)

The compound of claim 8, G2 is C1-C4 alkyl or halo, and G2 is in the 2, 3, or 4 position of the phenyl ring.

### Claim 11

A compound of Formula V:
or pharmaceutically acceptable salts thereof;
wherein
R4 is H or C1-C6 alkyl;
G1 is H or C1-C6 alkyl;
wherein each R5 is independently selected at each occurrence from the group consisting of —C1-C6 alkyl, halo, —CN, —NO2, -(L)m-OR8, -(L)m-SR9, -(L)m-S(═O)R9, -(L)m-S(═O)2R9, -(L)m-NHS(═O)2R9, -(L)mC(═O)R9, -(L)m-OC(═O)R9, -(L)mCO2R8, -(L)m-OCO2R8, -(L)m-CH(R8)2, -(L)m-N(R8)2, -(L)mC(═O)N(R8)2, -(L)m-OC(═O)N(R8)2, -(L)m-NHC(═O)NH(R8), -(L)m-NHC(═O)R9, -(L)m-NHC(═O)OR9, -(L)m-C(OH)(R8)2, -(L)mC(NH2)(R8)2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl and —C1-C6 trihaloalkyl;
L is independently, at each occurrence, a bivalent radical selected from —(C1-C3 alkylene)-, —(C3-C7 cycloalkylene)-, —(C1-C3 alkylene)m-O—(C1-C3 alkylene)m-, or —(C1-C3 alkylene)m-NH—(C1-C3 alkylene)m-;
each R8 is independently, at each occurrence, H, C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R2;
R9 is C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R2 is independently selected at each occurrence from the group consisting of halo, —OH, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl;
n is 1, 2, 3, 4, 5, or 6;
each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4;
each occurrence of y is independently selected from the group consisting of 1, 2, and 3;
each occurrence of m is independently 0, 1 or 2.

### Claim 12 (depends on 11)

The compound of claim 11, wherein
each R5 is independently selected at each occurrence from the group consisting of OH, C1-C6 alkyl, C1-C6 alkoxy, halo, —CN, —NO2, C1-C6 chloroalkyl, —C1-C6 dichloroalkyl, —C1-C6 trichloroalkyl, —C1-C6 fluoroalkyl, —C1-C6 difluoroalkyl and —C1-C6 trifluoroalkyl; and
R2 is independently selected at each occurrence from the group consisting of halo, —OH, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl.

### Claim 13 (depends on 11)

The compound of claim 11, wherein
each R5 is independently selected at each occurrence from the group consisting of —OH, C1-C6 alkyl, C1-C6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;
R2 is independently selected at each occurrence from the group consisting of —OH, halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl.

### Claim 14 (depends on 11)

The compound of claim 11 wherein each R5 is independently selected at each occurrence from the group consisting of —OH, C1-C6 alkyl, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl; and each R2 is independently selected at each occurrence from the group consisting of halo, —C1-C6 alkyl, or —C1-C6 alkoxy.

### Claim 15

A compound of Formula VI:
or pharmaceutically acceptable salts thereof;
wherein
R4 is H or C1-C6 alkyl;
G1 is H or C1-C6 alkyl;
wherein each R5 is independently selected at each occurrence from the group consisting of C1-C6alkyl, C1-C6 alkoxy, halo, —CN, —NO2, -(L)m-SR9, -(L)m-S(═O)R9, -(L)m-S(═O)2R9, -(L)m-NHS(═O)2R9, -(L)mC(═O)R9, -(L)m-OC(═O)R9, -(L)mCO2R8, -(L)m-OCO2R8, -(L)m-CH(R8)2, -(L)m-N(R8)2, -(L)mC(═O)N(R8)2, -(L)m-OC(═O)N(R8)2, -(L)m-NHC(═O)NH(R8), -(L)m-NHC(═O)R9, -(L)m-NHC(═O)OR9, -(L)mC(OH)(R8)2, -(L)mC(NH2)(R8)2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl and —C1-C6 trihaloalkyl;
L is independently, at each occurrence, a bivalent radical selected from —(C1-C3 alkylene)-, —(C3-C7 cycloalkylene)-, —(C1-C3 alkylene)m-O—(C1-C3 alkylene)m-, or —(C1-C3 alkylene)m-NH—(C1-C3 alkylene)m-;
each R8 is independently, at each occurrence, H, C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R2;
R9 is C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R10 is OH, C1-C6 alkyl, C1-C6 alkyl-OH, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R11 is a bond or C1-C3 alkylene, wherein the C1-C3 alkylene is optionally substituted with 1-3 substituents selected from R2;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl;
w is 0, 1 or 2;
each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3 and 4;
each occurrence of y is independently selected from the group consisting of 0, 1, 2, 3 and 4;
each occurrence of z is independently selected from the group consisting of 0, 1, 2, and 3;
each occurrence of m is independently 0, 1 or 2.

### Claim 16 (depends on 15)

The compound of claim 15, wherein
each R5 is independently selected at each occurrence from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halo, —CN, —NO2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, and —C1-C6 trihaloalkyl;
R10 is OH, halo, C1-C6 alkyl, C1-C6 alkyl-OH, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R11 is a bond or C1-C3 alkylene, wherein the C1-C3 alkylene is optionally substituted with 1-3 substituents selected from R2;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, C(O)—C1-C6 alkyl, and C(O)—C1-C6 alkoxy.

### Claim 17 (depends on 15)

The compound of claim 15, wherein
each R5 is independently selected at each occurrence from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halo, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, and trichloromethyl;
R10 is OH, halo, C1-C6 alkyl, C1-C6 alkyl-OH, C1-C6 fluoroalkyl, C1-C6 difluoroalkyl, C1-C6 trifluoroalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R11 is a bond or C1-C3 alkylene;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl, and C(O)—C1-C6 alkoxy.

### Claim at position 18

18-21. (canceled)

### Claim 22 (depends on 15)

The compound of claim 15, wherein the compound of Formula VI is of the Formula VIb:
or pharmaceutically acceptable salts thereof;
wherein X is halo;
G1 is hydrogen or halo;
G2 is H, C1-C4 alkyl, or halo; and
G4 is H, halo, C1-C4 alkyl, or OH.

### Claim 23

A compound of Formula VII:
or pharmaceutically acceptable salts thereof;
wherein
R4 is H or C1-C6 alkyl;
wherein each R5 is independently selected at each occurrence from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halo, —CN, —NO2, -(L)m-SR9, -(L)m-S(═O)R9, -(L)m-S(═O)2R9, -(L)m-NHS(═O)2R9, -(L)m-C(═O)R9, -(L)m-OC(═O)R9, -(L)mCO2R8, -(L)m-OCO2R8, -(L)m-CH(R8)2, -(L)m-N(R8)2, -(L)m-C(═O)N(R8)2, -(L)m-C(═O)N(R8)2, -(L)m-NHC(═O)NH(R8), -(L)m-NHC(═O)R9, -(L)m-NHC(═O)OR9, -(L)m-C(OH)(R8)2, -(L)mC(NH2)(R8)2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl and —C1-C6 trihaloalkyl;
L is independently, at each occurrence, a bivalent radical selected from —(C1-C3 alkylene)-, —(C3-C7 cycloalkylene)-, —(C1-C3 alkylene)m-O—(C1-C3 alkylene)m-, or —(C1-C3 alkylene)m-NH—(C1-C3 alkylene)m-;
each R8 is independently, at each occurrence, H, C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally substituted with 1-5 substituents selected from R2;
R9 is C1-C6 alkyl, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, —C1-C6 trihaloalkyl, C1-C6 heteroalkyl, C3-C10 cycloalkyl, a C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), and wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring is optionally substituted with 1-5 substituents selected from R2;
R10 is H, C1-C6 alkyl, -(L)m-C(═O)C1-C6 alkyl, -(L)m-C(═O)C3-C10 cycloalkyl, -(L)m-C(═O)OC1-C6 alkyl, -(L)m-C(═O)OC3-C10 cycloalkyl wherein the alkyl or cycloalkyl groups are optionally substituted with halo, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, or —C1-C6 trihaloalkyl;
R11 is a bond or C1-C3 alkylene, wherein the C1-C3 alkylene is optionally substituted with 0-3 substituents selected from R2;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, and C(O)—C1-C6 alkyl;
each occurrence of x is independently selected from the group consisting of 0, 1, 2, 3, or 4;
each occurrence of y is independently selected from the group consisting of 1, 2, and 3;
z is 0 or 1; and
each occurrence of m is independently 0, 1 or 2.

### Claim 24 (depends on 23)

The compound of claim 23, wherein
each R5 is independently selected at each occurrence from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, halo, —CN, —NO2, —C1-C6 haloalkyl, —C1-C6 dihaloalkyl, and —C1-C6 trihaloalkyl;
R11 is a bond or C1-C3 alkylene, wherein the C1-C3 alkylene is optionally substituted with 0-3 substituents selected from R2;
R2 is independently selected at each occurrence from the group consisting of halo, —CN, —NO2, —C1-C6 alkyl, —C1-C6 alkoxy, —C1-C6 fluoroalkyl, —C1-C6 heteroalkyl, C(O)—C1-C6 alkyl, and C(O)—C1-C6 alkoxy.

### Claim at position 22

25-28. (canceled)

### Claim 29 (depends on 1)

A composition comprising a compound according to any one of claim 1, or a salt, solvate or N-oxide-thereof.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the composition is pharmaceutical and further comprises at least one pharmaceutically acceptable carrier.

### Claim 31 (depends on 1)

A method of treating an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound according to claim 1.

### Claim at position 26

32-37. (canceled)

### Claim 38 (depends on 31)

The method of any of claim 31, further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, literature-described capsid assembly modulator, reverse transcriptase inhibitor, a TLR-agonist, and agents of distinct or unknown mechanism, and a combination thereof.

### Claim at position 28

39-46. (canceled)

### Claim 47 (depends on 11)

A method of treating-an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound according to claim 11.

### Claim 48 (depends on 15)

A method of treating-an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound according to claim 15.

### Claim 49 (depends on 23)

A method of treating-an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound according to claim 23.
